{"title":"Metabolic \u0026 Fat Loss Research","description":"\u003ch2 id=\"tinymce_scroll_sign\"\u003eUnderstanding Fat Loss Supplements UK: Research and Benefits\u003c\/h2\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eThe Science Behind Fat Loss Supplements UK\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eFat loss supplements UK have gained popularity as effective aids in enhancing metabolism and supporting weight management goals. Scientific research focuses on ingredients like caffeine, green tea extract, and L-carnitine, which help increase energy expenditure and fat oxidation. Understanding how these supplements interact with the body’s metabolic processes can empower consumers to make informed choices. Reliable fat loss supplements UK are formulated to complement diet and exercise, not replace them, ensuring a balanced approach to healthy weight loss.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eKey Ingredients in Fat Loss Supplements UK\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eMany fat loss supplements UK include natural ingredients known to promote metabolic rate and fat burning. These often include green coffee bean extract, conjugated linoleic acid (CLA), and forskolin. Each of these has been researched for its ability to influence fat metabolism or appetite control. Choosing supplements with clinically studied ingredients can improve fat loss outcomes while minimizing side effects, making it essential for consumers to review product labels carefully before purchasing fat loss supplements UK.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eHow to Choose the Right Fat Loss Supplements UK\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eSelecting the right fat loss supplements UK involves considering several factors like ingredient transparency, safety, and customer reviews. It’s vital to avoid products with unrealistic claims or harmful additives. Consulting healthcare professionals or nutritionists can provide additional guidance tailored to individual needs. Good fat loss supplements UK should support your metabolism and fat reduction goals while fitting safely within your overall lifestyle and diet plan for sustainable results.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","products":[{"product_id":"5-amino-1mq","title":"5-Amino-1MQ","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e5-Amino-1MQ | 5-Amino-1-Methylquinolinium | Selective NNMT Inhibitor | Research Compound\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFull Name:\u003c\/strong\u003e 5-Amino-1-Methylquinolinium \u003cstrong\u003eAlso Known As:\u003c\/strong\u003e 5-Amino-1MQ, NNMTi \u003cstrong\u003eMechanism:\u003c\/strong\u003e Selective, membrane-permeable inhibitor of Nicotinamide N-Methyltransferase (NNMT) \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₀H₁₁N₂⁺ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 159.21 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 63887-14-9\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is 5-Amino-1MQ?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ (5-Amino-1-Methylquinolinium) is a small, membrane-permeable synthetic molecule first characterised by researchers at the University of Texas Medical Branch in 2017. It was developed as a selective inhibitor of Nicotinamide N-Methyltransferase (NNMT) — a cytosolic enzyme responsible for methylating nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH) in the process.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWhile technically classified as a small molecule rather than a peptide, 5-Amino-1MQ has rapidly become one of the most actively studied research compounds in the fields of metabolic biology, NAD+ pathway research, and ageing science — and is frequently catalogued alongside research peptides given its overlapping research applications and target audience.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eNNMT is expressed at high levels in white adipose tissue, liver, skeletal muscle, brain, kidney, heart, and lung — and its expression increases markedly with age in muscle tissue, with one study reporting approximately three-fold higher NNMT protein expression in aged versus young muscle. Elevated NNMT activity has been consistently linked to metabolic dysfunction, obesity, insulin resistance, sarcopenia, and impaired NAD+ availability. By selectively inhibiting this enzyme, 5-Amino-1MQ disrupts a key metabolic bottleneck, redirecting nicotinamide flux back toward NAD+ synthesis via the salvage pathway — a mechanism that has generated substantial scientific interest across multiple research disciplines.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA critical advantage of 5-Amino-1MQ over many earlier NNMT inhibitors is its high membrane permeability. Confirmed by both PAMPA assay and bidirectional Caco-2 cell transport studies, this property enables the compound to cross cellular membranes effectively — a prerequisite for intracellular NNMT engagement that earlier inhibitors in this class lacked. Importantly, 5-Amino-1MQ has demonstrated high selectivity for NNMT, with preclinical data showing it does not inhibit related SAM-dependent methyltransferases or other enzymes in the NAD+ salvage pathway.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur 5-Amino-1MQ is manufactured under rigorous quality-controlled conditions, verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), and supplied as a lyophilised powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ has accumulated a compelling body of preclinical evidence since its introduction, spanning metabolic biology, skeletal muscle research, adipose tissue science, cardiovascular biology, and oncology. Its position at the intersection of NAD+ metabolism, methyl-donor homeostasis, and sirtuin signalling makes it one of the most mechanistically versatile research compounds currently available.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eThe NNMT-NAD+ Axis: Core Mechanism\u003c\/strong\u003e NNMT occupies a critical node in cellular metabolic regulation by consuming nicotinamide — the primary substrate for NAD+ biosynthesis via the salvage pathway — and diverting it toward methylated metabolite production. When NNMT activity is elevated, as it is in obesity, ageing, and metabolic disease states, intracellular NAD+ levels decline. This depletion has cascading downstream consequences: reduced sirtuin (SIRT1, SIRT3) activity, impaired mitochondrial function, disrupted energy sensing, and increased cellular senescence. By inhibiting NNMT, 5-Amino-1MQ preserves nicotinamide availability for NAD+ synthesis via nicotinamide mononucleotide (NMN), effectively boosting intracellular NAD+ without the need to supply exogenous NAD+ precursors. In vitro studies have confirmed that 5-Amino-1MQ treatment significantly increases intracellular NAD+ levels in both adipocyte and hepatocyte cell models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAdipose Tissue \u0026amp; Obesity Research\u003c\/strong\u003e The most extensively documented preclinical research on 5-Amino-1MQ concerns its effects in adipose tissue and diet-induced obesity models. In a landmark study published in Biochemical Pharmacology, obese mice treated with 5-Amino-1MQ demonstrated significant reductions in body weight, white adipose tissue mass, and adipocyte size relative to vehicle-treated controls — achieving body composition parameters comparable to lean control animals. These changes occurred without significant reduction in food intake, suggesting the effects were driven by increased energy expenditure rather than appetite suppression. In vitro, 5-Amino-1MQ suppressed lipogenesis and reduced intracellular 1-MNA levels in differentiated adipocytes, providing mechanistic support for the in vivo findings.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eInsulin Sensitivity \u0026amp; Glucose Metabolism\u003c\/strong\u003e Parallel to its effects on fat mass, 5-Amino-1MQ has been studied in models of insulin resistance and type 2 diabetes. Preclinical data in diet-induced obese mouse models demonstrated marked improvements in insulin sensitivity, with one study observing reductions in serum insulin levels of 50–60% alongside normalisation of glucose tolerance and fasting blood glucose. These findings are consistent with the known role of NNMT in adipose tissue insulin signalling and have led researchers to position NNMT inhibition — and 5-Amino-1MQ specifically — as a mechanistically novel and complementary approach to existing metabolic disease research tools.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSkeletal Muscle \u0026amp; Sarcopenia Research\u003c\/strong\u003e A significant and rapidly expanding body of literature has examined 5-Amino-1MQ in models of skeletal muscle ageing and regeneration. NNMT expression increases approximately three-fold in aged versus young muscle tissue, and this overexpression has been identified as a dominant component of the gene expression signature for sarcopenia. Elevated NNMT activity in aged muscle is associated with impaired NAD+ availability, dysregulated SIRT1 activity, and increased muscle stem cell (satellite cell; MuSC) senescence — all contributors to the decline in regenerative capacity that characterises ageing muscle.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn a pivotal study examining aged mouse models of muscle injury, NNMT inhibitor treatment with 5-Amino-1MQ rescued muscle stem cell function, producing nearly two-fold greater cross-sectional area (CSA) in regenerated myofibres and significantly shifting fibre size distribution toward larger, functionally superior fibres compared to untreated controls. Contractile force in healed muscle was approximately 70% greater in the 5-Amino-1MQ treated group.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA subsequent 2024 study published in Scientific Reports (University of Texas Medical Branch) directly compared exercise training alone versus exercise training combined with 5-Amino-1MQ in aged mice. The addition of 5-Amino-1MQ to the exercise protocol produced approximately 150% increases in daily running distance that were sustained over the study period — compared to an initial 75% increase that tapered significantly with exercise alone. Grip strength improvements also exceeded those achieved by exercise training in isolation, leading researchers to describe 5-Amino-1MQ as producing additive effects beyond exercise through mechanistic pathways distinct from training adaptation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMethyl-Donor Metabolism \u0026amp; Epigenetic Research\u003c\/strong\u003e NNMT's consumption of SAM — the universal methyl donor — places it at the centre of epigenetic regulation as well as metabolic biology. When NNMT is overactive, SAM availability for other methyltransferases is reduced, potentially disrupting DNA methylation, histone methylation, and other epigenetically regulated processes. 5-Amino-1MQ, by inhibiting NNMT, preserves SAM availability for these competing methylation reactions. This intersection of metabolic and epigenetic regulation has made NNMT — and by extension, 5-Amino-1MQ — a subject of growing interest in ageing biology and epigenetic research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e NNMT's role in cardiovascular pathophysiology has become an active area of research, with the enzyme's upregulation linked to atherosclerosis, hypertension, and myocardial ischaemia through multiple pathways. NNMT-mediated NAD+ depletion impairs sirtuin activity and mitochondrial antioxidant defences, while elevated homocysteine levels resulting from SAH accumulation activate pro-inflammatory cascades including TLR4–NF-κB and STAT3–IL-1β signalling. A 2025 review in Biomolecules identified 5-Amino-1MQ as one of the leading candidate NNMT inhibitors for cardiovascular therapeutic research, noting its selectivity and membrane permeability as key pharmacological advantages. No clinical trials in cardiovascular disease have yet been conducted with NNMT inhibitors, making this an open and compelling frontier for preclinical research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eOncology Research\u003c\/strong\u003e Emerging preclinical evidence suggests NNMT plays a role in tumour biology. NNMT overexpression has been observed in several cancer types, and its activity has been linked to epithelial-mesenchymal transition (EMT), tumour stroma remodelling, and enhanced migratory and invasive capacity in cancer cell lines. While 5-Amino-1MQ has not been the primary tool in all oncology-focused NNMT studies, the mechanistic connection between NNMT activity and cancer-associated metabolic reprogramming has positioned NNMT inhibition as an area of growing research interest in experimental oncology.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCompound\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5-Amino-1MQ (5-Amino-1-Methylquinolinium)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClass\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelective NNMT inhibitor (small molecule)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₁₀H₁₁N₂⁺\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e159.21 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or DMSO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMembrane Permeability\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eHigh (confirmed by PAMPA and Caco-2 assay)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelectivity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eHigh — does not inhibit related SAM-dependent methyltransferases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e63887-14-9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our 5-Amino-1MQ undergoes a comprehensive quality control process prior to release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms compound purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity and structural integrity\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing, giving researchers the confidence required for reproducible and reliable experimental work.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ lyophilised powder is soluble in sterile water or DMSO, depending on the experimental protocol. For aqueous reconstitution, gently swirl in sterile bacteriostatic water until fully dissolved. If using DMSO, ensure downstream dilution into aqueous buffer is performed to maintain cell viability in cell-based assays. Once reconstituted, aliquot immediately and store at –20°C. Avoid repeated freeze-thaw cycles to preserve compound integrity and experimental reproducibility.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e5-Amino-1MQ in Context: Relationship to Other Catalogue Compounds\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ occupies a distinctive and complementary position within our research catalogue. Its mechanism — NNMT inhibition leading to elevated intracellular NAD+ — places it in a direct functional relationship with MOTS-c, which operates at the level of mitochondrial signalling and AMPK activation. Both compounds converge on cellular energy metabolism and represent complementary tools for researchers studying metabolic ageing and bioenergetics from different mechanistic angles.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFor researchers working on metabolic dysfunction, 5-Amino-1MQ also provides a mechanistically distinct perspective relative to the receptor-level hormonal signalling approach of retatrutide. While retatrutide acts systemically via GIP, GLP-1, and glucagon receptors to modulate energy homeostasis, 5-Amino-1MQ operates intracellularly — directly at the level of NAD+ availability and methyl-donor metabolism — offering researchers a complementary tool for multi-pathway metabolic research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll compounds in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. 5-Amino-1MQ has not entered clinical trials and is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105050958,"sku":null,"price":28.99,"currency_code":"GBP","in_stock":true},{"title":"50mg","offer_id":59643105083726,"sku":null,"price":78.88,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_173347_d68e0f93-5cc2-4b5f-a64c-365cdd923c24.png?v=1779451009"},{"product_id":"bacteriostatic-water-bac-water","title":"Bacteriostatic Water (BAC Water)","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBacteriostatic Water | BAC Water | Sterile Peptide Reconstitution Solution | Research Grade\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eComposition:\u003c\/strong\u003e Sterile water for injection + 0.9% benzyl alcohol (9 mg\/mL) \u003cstrong\u003eGrade:\u003c\/strong\u003e Research grade — sterile, pyrogen-free \u003cstrong\u003ePreservative:\u003c\/strong\u003e Benzyl alcohol 0.9% (v\/v) \u003cstrong\u003epH:\u003c\/strong\u003e 4.5–7.0 \u003cstrong\u003eAppearance:\u003c\/strong\u003e Clear, colourless solution \u003cstrong\u003ePackaging:\u003c\/strong\u003e Sealed multi-dose vials \u003cstrong\u003eStorage:\u003c\/strong\u003e Room temperature (15–25°C), away from light; refrigerate after opening\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Bacteriostatic Water?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBacteriostatic water (BAC water) is a preparation of sterile water for injection containing 0.9% benzyl alcohol (9 mg\/mL) as a preservative. The term \"bacteriostatic\" refers to the benzyl alcohol component — a broad-spectrum antimicrobial agent that inhibits bacterial growth and multiplication within the vial, without necessarily killing bacteria outright. This preservative action allows BAC water to remain safely usable across multiple withdrawals over an extended period — a critical property that distinguishes it from standard sterile water for injection, which is intended for single-use only and carries no microbial protection after the vial seal is first broken.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBAC water is the standard reconstitution vehicle for a wide range of lyophilised research peptides, proteins, and biological compounds — including human growth hormone (HGH), GHRFs, GHRPs, and most synthetic research peptides. It is used wherever a multi-dose reconstitution protocol is required, and where peptide or protein stability across multiple draw-down events must be maintained without microbial contamination risk.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur bacteriostatic water is manufactured to research grade: sterile, pyrogen-free, and packaged in sealed multi-dose vials with halogenated butyl stoppers compatible with standard research syringes and needle gauges.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhy BAC Water Matters for Peptide Research\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe choice of reconstitution vehicle is one of the most practically consequential decisions in peptide research — and one that is frequently underestimated. Using an inappropriate reconstitution solution can compromise peptide stability, alter solubility, affect experimental reproducibility, and — in the case of multi-dose vials — introduce microbial contamination that invalidates results and degrades the compound.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBacteriostatic water addresses these concerns by providing a chemically inert, pH-appropriate, sterile environment with sustained antimicrobial protection across repeated vial access events. For researchers working with lyophilised peptides that require reconstitution before use — including every compound in our research catalogue — BAC water is the most broadly appropriate and widely used reconstitution vehicle in the scientific literature.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCompatibility with our catalogue:\u003c\/strong\u003e BAC water is the recommended reconstitution vehicle for HGH (somatotropin), tesamorelin, BPC-157, TB-500, MOTS-c, Selank, and the majority of other lyophilised research peptides. GHK-Cu is optimally reconstituted in sterile water or PBS, and 5-Amino-1MQ may require DMSO for certain protocols — but for the majority of peptide reconstitution applications, BAC water is the first-choice solution.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eComposition \u0026amp; Technical Specifications\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy 0.9% benzyl alcohol?\u003c\/strong\u003e Benzyl alcohol has been used as an antimicrobial preservative in injectable preparations since the 1920s. At 0.9% concentration, it provides effective bacteriostatic activity against a broad spectrum of gram-positive and gram-negative bacteria — the most likely contaminants in a multi-access vial environment — while remaining chemically compatible with the widest range of peptides, proteins, and hormones used in research. Higher benzyl alcohol concentrations can begin to affect protein folding and stability; 0.9% represents the established standard for balancing preservation efficacy with compound compatibility.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy not sterile water for injection?\u003c\/strong\u003e Standard sterile water for injection (SWFI) contains no preservative and is intended for single-use only. Once the seal is broken and the vial accessed, SWFI provides no protection against bacterial contamination from subsequent needle insertions. For researchers who routinely draw multiple aliquots from a single reconstituted vial over days or weeks — as is standard practice with peptide research compounds — SWFI is inappropriate and significantly increases the risk of microbial contamination that will degrade the compound and compromise experimental results.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy not saline or PBS?\u003c\/strong\u003e Normal saline (0.9% sodium chloride) and phosphate-buffered saline (PBS) are appropriate for some peptide reconstitution applications but carry important caveats. Saline can reduce the solubility of certain peptides and proteins and provides no preservative action in multi-dose vials. PBS introduces phosphate and salt ions that can interact with some peptides and alter their behaviour in downstream assays. For most lyophilised research peptide applications, BAC water provides a cleaner, more universally compatible, and more practically convenient reconstitution vehicle.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBAC Water and Peptide Stability\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eProper reconstitution practice is as important as purity when it comes to preserving the integrity and research utility of lyophilised peptides. The following principles apply to reconstitution with BAC water across the research peptide catalogue:\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTechnique:\u003c\/strong\u003e Always inject BAC water slowly against the side of the vial — never directly onto the lyophilised powder, which can mechanically disrupt peptide structure. Swirl gently until dissolved; do not shake or vortex.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTemperature:\u003c\/strong\u003e Allow the lyophilised vial to reach room temperature before reconstitution. Cold powder reconstituted with room-temperature water can produce localised concentration gradients that slow dissolution.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eStorage after reconstitution:\u003c\/strong\u003e Reconstituted peptides in BAC water should be stored at 2–8°C (refrigerated). The benzyl alcohol preservative protects against microbial growth but does not prevent peptide degradation from heat or light exposure. Reconstituted solutions should be used within the timeframes recommended for each specific compound — typically 28 days for HGH and tesamorelin, and up to 30 days for shorter synthetic peptides, though this varies by compound.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFreeze-thaw:\u003c\/strong\u003e Reconstituted peptide solutions in BAC water should not be re-frozen unless the specific compound's data sheet indicates this is acceptable. For long-term storage, lyophilise in advance of reconstitution or aliquot before the first freeze-thaw cycle.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eComposition\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWater for injection + 0.9% benzyl alcohol (9 mg\/mL)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGrade\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eResearch grade — sterile, pyrogen-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePreservative\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eBenzyl alcohol 0.9% (v\/v)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003epH\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e4.5–7.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eOsmolality\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~9 mOsm\/kg (hypotonic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClear, colourless solution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePackaging\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSealed multi-dose vials with halogenated butyl stopper\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eRoom temperature (15–25°C), away from light; refrigerate after opening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAs labelled on vial; discard 28 days after first opening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur bacteriostatic water is manufactured to research-grade standards:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSterility Testing\u003c\/strong\u003e — confirmed sterile, free from viable microorganisms\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePyrogen \/ Endotoxin Testing\u003c\/strong\u003e — confirmed pyrogen-free by LAL (Limulus Amebocyte Lysate) assay\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eBenzyl Alcohol Content\u003c\/strong\u003e — verified at 0.9% (9 mg\/mL) by validated assay\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003epH Verification\u003c\/strong\u003e — confirmed within the 4.5–7.0 range\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eParticulate Matter Testing\u003c\/strong\u003e — confirmed free from visible particulates\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eEssential Accessory for Every Peptide Researcher\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBAC water is a consumable that every serious research peptide laboratory requires. We recommend maintaining an adequate supply to support your full research protocol — running out mid-study and substituting an alternative reconstitution vehicle can introduce a variable that undermines experimental comparability. Given the investment represented by high-purity research peptides, using a matched, research-grade reconstitution solution is a straightforward way to protect that investment and maintain the integrity of your experimental data.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIf you are purchasing any lyophilised peptide from our catalogue — whether BPC-157, TB-500, GHK-Cu, MOTS-c, Selank, tesamorelin, HGH, retatrutide, or any other compound — we recommend including bacteriostatic water in your order.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for research and laboratory use only. Bacteriostatic water containing benzyl alcohol is not approved for use in neonates or premature infants, in whom benzyl alcohol toxicity has been documented at high doses. This product must not be self-administered or used outside of appropriately supervised research or clinical contexts. By purchasing this product, the buyer confirms they are a qualified researcher and will use it solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"10ml","offer_id":59643105149262,"sku":null,"price":7.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_165507_cb36c0a9-b827-4e01-bba7-05b9129f574b.png?v=1779451016"},{"product_id":"bpc-157","title":"BPC-157","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBPC-157 | Body Protection Compound-157 | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₆₂H₁₀₀N₁₆O₂₂ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1419.53 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 137525-51-0\u003cbr\u003e\u003cbr\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/BPC157-2026-nexyra_lab-Peptides-Certificate-of-analysis-2026.pdf?v=1780398927\"\u003e\u003cimg height=\"58\" width=\"58\" alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/ChatGPT_Image_Jun_2_2026_12_28_15_PM_b6a095fc-de0a-454a-870d-2005dacd857d.png?v=1780407285\"\u003e\u003c\/a\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is BPC-157?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a partial sequence of Body Protection Compound, a protein naturally found in human gastric juice. First identified and isolated in the 1990s, BPC-157 has since become one of the most actively studied peptides in preclinical research, attracting significant scientific interest for its pleiotropic biological activity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur BPC-157 is produced under strict quality-controlled conditions, achieving a verified purity of greater than 99% as confirmed by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). It is supplied in lyophilised (freeze-dried) form to ensure maximum stability and shelf life.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBPC-157 has been the subject of numerous peer-reviewed preclinical studies, the majority conducted in rodent models. Researchers across gastroenterology, orthopaedics, neuroscience, and pharmacology have explored the compound's interaction with multiple biological pathways.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eKey areas of active research include:\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTissue and Wound Healing\u003c\/strong\u003e Preclinical studies have investigated BPC-157's influence on angiogenesis — the formation of new blood vessels — and fibroblast activity. Research published in peer-reviewed journals suggests the compound may interact with the nitric oxide (NO) system, which plays a central role in vascular regulation and tissue repair mechanisms.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGastrointestinal Research\u003c\/strong\u003e Given its origin from gastric juice proteins, BPC-157 has drawn considerable attention in GI research. Animal studies have explored its effects on gastric ulcer models, inflammatory bowel conditions, and intestinal anastomosis healing, with researchers observing notable cytoprotective responses in mucosal tissue models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMusculoskeletal \u0026amp; Tendon Models\u003c\/strong\u003e A growing body of preclinical literature has examined BPC-157 in models involving tendon, ligament, bone, and muscle tissue. Researchers have observed upregulation of growth hormone receptor expression in tendon fibroblast cell lines — a finding that has generated further mechanistic inquiry.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eNeurological \u0026amp; Dopaminergic Pathways\u003c\/strong\u003e Some preclinical research has investigated BPC-157's interaction with dopaminergic and serotonergic systems, as well as its potential neuroprotective properties in brain lesion and traumatic injury models. These findings remain in early exploratory stages and warrant further rigorous study.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAnti-inflammatory Mechanisms\u003c\/strong\u003e BPC-157 has been studied in models of inflammation, with research suggesting modulation of inflammatory cytokine activity. Its interaction with the VEGFR2-Akt-eNOS signalling pathway is one proposed mechanism currently under investigation.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\" scope=\"col\"\u003eSpecification\u003c\/th\u003e\n\u003cth class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\" scope=\"col\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eBPC-157 (Body Protection Compound-157)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in water or dilute acetic acid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e137525-51-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our BPC-157 undergoes rigorous third-party testing before release. Our quality assurance process includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity and sequence integrity\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWe are committed to supplying researchers with the highest-grade peptides available on the market. Consistency, traceability, and transparency are central to our quality standards.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBPC-157 lyophilised powder should be reconstituted using sterile bacteriostatic water or dilute acetic acid (0.1%) depending on the experimental protocol. Once reconstituted, the solution should be aliquoted and stored at –20°C to preserve stability and avoid repeated freeze-thaw cycles, which can degrade peptide integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eResearchers should handle all peptides in accordance with standard laboratory safety practices and applicable institutional guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. BPC-157 is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5","offer_id":59643105280334,"sku":null,"price":17.99,"currency_code":"GBP","in_stock":true},{"title":"10","offer_id":59643105313102,"sku":null,"price":31.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_184747_4f3584b7-b898-4af1-bc24-2d46f05d173f.png?v=1779451020"},{"product_id":"ipamorelin","title":"Ipamorelin","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | Selective GHS-R1a Agonist | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Aib-His-D-2-Nal-D-Phe-Lys-NH₂ \u003cstrong\u003eClassification:\u003c\/strong\u003e Synthetic pentapeptide — selective growth hormone secretagogue receptor 1a (GHS-R1a) agonist \/ GHRP \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₃₈H₄₉N₉O₅ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 711.85 g\/mol \u003cstrong\u003eKey Structural Features:\u003c\/strong\u003e α-aminoisobutyric acid (Aib) at position 1; D-2-naphthylalanine (D-2-Nal) at position 3; D-phenylalanine (D-Phe) at position 4 \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 170851-70-4\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Ipamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) and selective agonist of the ghrelin receptor (GHS-R1a), originally developed by Novo Nordisk in Denmark and first characterised in a landmark 1998 paper in the European Journal of Endocrinology by Raun and colleagues. It was derived from GHRP-1 through a systematic chemistry programme that identified active analogues lacking the central Ala-Trp dipeptide of the parent compound, ultimately yielding ipamorelin as the most pharmacologically refined member of its series.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin's significance in the research peptide landscape rests on a single, defining characteristic: it is the first growth hormone-releasing peptide receptor agonist to demonstrate a selectivity for GH release comparable to that of endogenous GHRH itself. All earlier GHRPs — including GHRP-2 and GHRP-6 — stimulated GH release but also produced dose-dependent elevations in ACTH and cortisol through activation of broader stress-response signalling pathways. Ipamorelin does not. In the foundational Novo Nordisk pharmacology studies, ipamorelin failed to elevate ACTH or cortisol at doses more than 200-fold above its ED50 for GH release — a specificity profile that had not previously been achieved with any GHRP receptor agonist and that fundamentally changed the landscape of GH secretagogue research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eStructurally, ipamorelin incorporates three key non-natural amino acid features that underpin its selectivity and metabolic stability. The α-aminoisobutyric acid (Aib) residue at position 1 confers resistance to N-terminal peptidase cleavage. The D-2-naphthylalanine (D-2-Nal) at position 3 — a bulky, non-natural amino acid — provides critical receptor binding contributions and contributes to selectivity. The D-phenylalanine (D-Phe) at position 4 further stabilises the receptor-bound conformation. Together, these modifications produce a compound with substantially lower systemic plasma clearance than GHRP-6 — approximately five-fold lower — and moderate resistance to metabolic degradation, resulting in a more sustained and reproducible GH secretory response.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs by acting at the ghrelin receptor (GHS-R1a) — a distinct and mechanistically complementary pathway to the GHRH receptor pathway through which CJC-1295 No DAC and tesamorelin operate. This mechanistic distinction is the basis of the well-established synergistic relationship between ipamorelin and GHRH analogues in GH secretion research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur ipamorelin is synthesised under rigorous quality-controlled manufacturing conditions, verified to a purity of greater than 99% by HPLC and Mass Spectrometry, and supplied as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin has accumulated a rich and diverse body of preclinical research since its characterisation in 1998, spanning GH secretagogue pharmacology, metabolic biology, bone mineral density, gastrointestinal motility, and body composition research. Its defining selectivity profile has made it the reference compound of choice for ghrelin receptor agonism research where hormonal specificity is a priority experimental requirement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGHS-R1a Receptor Pharmacology \u0026amp; Selectivity\u003c\/strong\u003e Ipamorelin's receptor pharmacology was comprehensively characterised in the original Novo Nordisk studies. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy closely comparable to GHRP-6 — achieving an EC50 of 1.3 ± 0.4 nmol\/L and an Emax of 85 ± 5% relative to GHRP-6's 100% reference maximum. In vivo, in conscious swine — a model with GH axis pharmacology closely reflective of human GH secretion — ipamorelin produced an ED50 of 2.3 ± 0.03 nmol\/kg and an Emax of 65 ± 0.2 ng GH\/mL plasma, comparable to GHRP-6 (ED50 3.9 ± 1.4 nmol\/kg, Emax 74 ± 7 ng\/mL) but with substantially superior selectivity. Critically, pharmacological profiling using both GHRP receptor antagonists and GHRH antagonists confirmed that ipamorelin stimulates GH release exclusively via the GHRP\/ghrelin receptor pathway — the same receptor used by GHRP-2 and GHRP-6 — rather than through the GHRH receptor. This orthogonal mechanism is the mechanistic basis of the synergistic GH release observed when ipamorelin is combined with GHRH analogues such as CJC-1295 No DAC.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eHormonal Selectivity: No ACTH, Cortisol, Prolactin or Gonadotropin Elevation\u003c\/strong\u003e The most scientifically significant finding in the ipamorelin pharmacology literature is its hormonal selectivity profile. In the definitive swine selectivity study, none of the GH secretagogues tested — including ipamorelin, GHRP-6, and GHRP-2 — affected FSH, LH, prolactin, or TSH levels. However, administration of both GHRP-6 and GHRP-2 produced significant elevations in plasma ACTH and cortisol. Ipamorelin produced no significant elevation in ACTH or cortisol at any dose tested — including doses exceeding 200-fold the GH-releasing ED50. This was described by the original authors as \"very surprising\" and represented a categorically different selectivity profile from all previously characterised GHRP receptor agonists. The practical research implication is substantial: studies using ipamorelin to investigate GH\/IGF-1 axis effects are not confounded by concurrent activation of the hypothalamic-pituitary-adrenal (HPA) axis — a major experimental advantage over GHRP-2 and GHRP-6 in any protocol where cortisol or ACTH are outcome variables, or where HPA axis activation would represent an uncontrolled experimental variable.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePulsatile GH Secretion \u0026amp; IGF-1 Axis Research\u003c\/strong\u003e Like CJC-1295 No DAC, ipamorelin stimulates pulsatile rather than continuous GH secretion. Its half-life of approximately two hours in rodent models — longer than GHRP-6 due to its approximately five-fold lower systemic plasma clearance — produces GH pulses of meaningful duration while preserving the inter-pulse intervals that allow natural somatostatin feedback to operate. Elevated GH secretion drives downstream IGF-1 production, mediated primarily through hepatic GH receptor signalling, and the GH\/IGF-1 axis effects of ipamorelin — including anabolic signalling in skeletal muscle, lipolytic activity in adipose tissue, and effects on bone metabolism — have been studied in multiple preclinical models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBone Mineral Density Research\u003c\/strong\u003e Ipamorelin has been studied in models of bone metabolism, with preclinical data demonstrating increases in bone mineral content (BMC) in treated female rats as measured by dual-energy X-ray absorptiometry (DXA) in vivo. Comparative studies examining ipamorelin and GHRP-6 both demonstrated BMC increases, consistent with the known role of the GH\/IGF-1 axis in bone formation, periosteal expansion, and endochondral ossification. These findings have positioned ipamorelin as a tool of interest in preclinical osteoporosis research and models of GH deficiency-associated bone loss.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGastrointestinal Motility Research\u003c\/strong\u003e The GHS-R1a receptor is expressed not only in the pituitary and hypothalamus but throughout the gastrointestinal tract — reflecting the physiological role of ghrelin as a gut-derived hormone regulating gastric motility and appetite. Ipamorelin has been studied in preclinical models of gastrointestinal dysfunction, including postoperative ileus (POI) — a clinically important condition characterised by delayed gastric emptying following abdominal surgery. Studies by Greenwood-Van Meerveld and colleagues using rodent POI models demonstrated that ipamorelin produced dose-dependent improvements in gastric emptying and reversal of POI-induced delayed gastrointestinal transit, with effects mediated through GHS-R1a expressed in gastrointestinal smooth muscle and enteric nervous system tissue. These findings have expanded ipamorelin's research relevance into gastrointestinal biology beyond its primary GH secretagogue profile.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBody Composition \u0026amp; Metabolic Research\u003c\/strong\u003e The downstream metabolic effects of ipamorelin-stimulated GH\/IGF-1 axis activation — including GH-mediated lipolysis in adipose tissue, IGF-1-mediated skeletal muscle protein synthesis, and nitrogen retention — have made ipamorelin a useful tool in preclinical body composition research. Studies have examined ipamorelin in models of lean mass accretion, visceral fat reduction, and metabolic syndrome, with findings consistent with the broader GH\/IGF-1 axis literature. Its hormonal selectivity — specifically the absence of cortisol elevation — is a meaningful research advantage in these models, as elevated cortisol has well-documented catabolic effects on muscle tissue that would otherwise confound body composition outcomes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCombination Research: Ipamorelin + CJC-1295 No DAC (GHRH + GHRP Synergy)\u003c\/strong\u003e One of the most important and widely replicated findings in GH secretagogue research is the synergistic relationship between GHRH-axis peptides and GHRP-class peptides in stimulating GH release. When a GHRH analogue (such as CJC-1295 No DAC) and a GHRP (such as ipamorelin) are administered together, the combined GH release substantially exceeds the sum of the individual responses — a finding consistent with the well-established physiological synergism between the hypothalamic GHRH and ghrelin systems. This occurs because the two compounds act through distinct and mechanistically independent receptors (GHRH-R and GHS-R1a respectively), and their downstream signalling cascades converge synergistically at the level of pituitary somatotroph GH secretion. This combination paradigm — CJC-1295 No DAC paired with ipamorelin — has become one of the most commonly used experimental protocols in preclinical GH-axis research, and both compounds are available in our catalogue to support this research design.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin vs. GHRP-2 and GHRP-6: Selectivity Comparison\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eParameter\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eIpamorelin\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eGHRP-6\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eGHRP-2\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGH release potency (swine)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~2.3 nmol\/kg\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~3.9 nmol\/kg\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~0.6 nmol\/kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGH release efficacy (swine)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~65 ng\/mL\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~74 ng\/mL\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~56 ng\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eACTH\/cortisol elevation\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone (even at 200× ED50)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eProlactin\/gonadotropin effects\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePlasma clearance vs GHRP-6\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~5× lower\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eReference\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLower than GHRP-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppetite \/ gastric effects\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMild (GHS-R1a mediated)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThis table illustrates why ipamorelin has become the preferred GHRP for researchers where hormonal specificity and clean pharmacology are experimental priorities — delivering comparable GH release potency to GHRP-6 while eliminating the ACTH and cortisol confounders that complicate interpretation of results with the older compounds.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eIpamorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAib-His-D-2-Nal-D-Phe-Lys-NH₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClassification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelective GHS-R1a agonist \/ GHRP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₃₈H₄₉N₉O₅\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e711.85 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile bacteriostatic water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e170851-70-4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our ipamorelin undergoes a comprehensive multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, non-natural amino acid incorporation (Aib, D-2-Nal, D-Phe), and full pentapeptide sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe three non-natural amino acids in ipamorelin — Aib, D-2-Nal, and D-Phe — are analytically critical features that distinguish it from related GHRPs. Our MS verification process explicitly confirms their incorporation to ensure the correct compound is delivered with research-grade accuracy and batch-to-batch consistency.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin lyophilised powder should be reconstituted using sterile bacteriostatic water. Inject slowly against the side of the vial and swirl gently — do not vortex. Once reconstituted, aliquot and store at 2–8°C. Use within 28–30 days of reconstitution. The compound exhibits moderate resistance to metabolic degradation in solution, but repeated freeze-thaw cycles should nonetheless be avoided to maintain research-grade integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin occupies the ghrelin receptor agonist \/ GHRP position within our GH-axis research toolkit — mechanistically complementary to, and synergistic with, the GHRH-axis compounds CJC-1295 No DAC and tesamorelin, and distinct from the direct GH replacement approach of rhGH.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader catalogue, ipamorelin's GHS-R1a-mediated GH\/IGF-1 axis activity is mechanistically distinct from the tissue-repair focus of BPC-157 and TB-500, the genomic and matrix biology of GHK-Cu, the mitochondrial metabolic signalling of MOTS-c, the systemic triple hormonal agonism of retatrutide, the intracellular NAD+ axis of 5-Amino-1MQ, and the neuropeptide biology of Selank. Our full GH axis research toolkit now comprises three distinct mechanistic entry points: ghrelin receptor agonism (ipamorelin), GHRH receptor agonism (CJC-1295 No DAC, tesamorelin), and direct GH replacement (rhGH) — providing researchers with the tools to study GH biology from upstream secretagogue stimulation through to receptor-level replacement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides are manufactured to the same \u0026gt;99% purity standard and supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. Ipamorelin is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105542478,"sku":null,"price":15.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643105575246,"sku":null,"price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_161949_79447409-1a83-4bd4-8386-ce029588bbff.png?v=1779451031"},{"product_id":"mots-c-1","title":"Mots-c","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eMOTS-c | Mitochondrial Open Reading Frame of the 12S rRNA-c | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Gln-Ala-Val-Thr-Pro-Gly-Gly-Leu-Leu-Leu-Gly-Ala-Pro-Pro-Ile-Pro-Tyr-Arg-Ile-Pro-Ile-Pro-Gly-Ser-Ser-Val-Tyr \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₂₁H₂₀₀N₃₄O₃₂ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 2174.5 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 1627580-64-6\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is MOTS-c?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded not by the nuclear genome, but by the mitochondrial genome — specifically within the 12S ribosomal RNA gene. It was first identified and characterised by researchers at the University of Southern California in 2015, making it one of the most recently discovered members of a new class of signalling molecules known as mitochondrial-derived peptides (MDPs).\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe discovery of MOTS-c fundamentally expanded scientific understanding of mitochondrial biology. Previously regarded primarily as the cell's energy-producing organelles, mitochondria are now understood to function as active endocrine-like signalling centres — capable of producing bioactive peptides that communicate with the nucleus, peripheral tissues, and systemic metabolic systems. MOTS-c is the most extensively studied of these mitochondrial peptides and has rapidly become a subject of considerable scientific interest.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eLike GHK-Cu, circulating MOTS-c levels in humans appear to decline with age, and this pattern has made it a compelling target for researchers studying metabolic ageing, insulin sensitivity, and cellular stress response. Circulating MOTS-c has also been shown to vary with exercise intensity in human subjects — a finding that has accelerated research interest across exercise science and metabolic biology.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur MOTS-c is synthesised under rigorous quality-controlled manufacturing conditions, achieving a verified purity of greater than 99% as confirmed by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). It is supplied as a lyophilised (freeze-dried) powder to ensure maximum stability throughout storage and shipping.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSince its discovery in 2015, MOTS-c has been the subject of an expanding body of peer-reviewed preclinical literature. Research spans metabolic science, exercise physiology, ageing biology, immunology, and cardiovascular science. Its unique mitochondrial origin and its apparent role as a systemic metabolic regulator distinguish it from all other peptides in this catalogue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMitochondrial Origin \u0026amp; Retrograde Signalling\u003c\/strong\u003e MOTS-c is translated within the mitochondria from a short open reading frame embedded in the 12S rRNA gene — a region long considered non-coding. Upon synthesis, MOTS-c is exported into the cytoplasm and, under conditions of cellular stress, translocates to the nucleus where it modulates gene expression. This mitochondria-to-nucleus retrograde signalling pathway is a defining feature of MOTS-c biology and a key reason it has attracted substantial mechanistic research interest. It represents a fundamentally new axis of intracellular communication.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eInsulin Sensitivity \u0026amp; Glucose Metabolism\u003c\/strong\u003e The most extensively studied aspect of MOTS-c activity involves glucose metabolism and insulin signalling. Preclinical research in rodent models has demonstrated that MOTS-c administration improves insulin sensitivity and reduces fasting blood glucose in diet-induced obesity models. Studies have identified AMPK (AMP-activated protein kinase) activation as a central mechanism — MOTS-c appears to promote AMPK phosphorylation, thereby enhancing glucose uptake and fatty acid oxidation in skeletal muscle. This positions MOTS-c among the most mechanistically interesting peptides in metabolic research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eExercise Mimicry \u0026amp; Skeletal Muscle Research\u003c\/strong\u003e One of the most striking findings in MOTS-c research is its apparent relationship with physical exercise. Studies have shown that circulating MOTS-c levels rise in response to aerobic exercise in both animal models and human subjects. Furthermore, exogenous MOTS-c administration in sedentary rodent models has produced metabolic adaptations partially overlapping with those induced by exercise — including increased mitochondrial biogenesis markers, improved fat oxidation, and enhanced skeletal muscle glucose utilisation. This has led researchers to describe MOTS-c as a candidate \"exercise mimetic\" peptide, making it a subject of significant interest in metabolic and sports science research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAge-Related Decline \u0026amp; Longevity Research\u003c\/strong\u003e Circulating MOTS-c concentrations decline measurably with age in both animal and human studies, and this age-associated reduction correlates with metabolic deterioration. Conversely, centenarian populations have been observed to maintain relatively higher MOTS-c plasma levels compared to age-matched controls — a finding that has generated substantial interest in longevity research. Preclinical studies in aged mouse models have demonstrated that MOTS-c supplementation can partially restore metabolic function and physical performance, reinforcing its candidacy as a target in ageing biology research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eInflammatory Response \u0026amp; Immune Modulation\u003c\/strong\u003e More recent research has begun to examine MOTS-c's role in immune and inflammatory regulation. Preclinical studies have observed that MOTS-c modulates macrophage activity and attenuates inflammatory cytokine expression — including IL-6 and TNF-α — in models of systemic inflammation. Its role in regulating the innate immune response to metabolic stress is an active and rapidly evolving area of investigation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e Emerging preclinical evidence suggests MOTS-c may exert cardioprotective effects. Studies in cardiac ischaemia-reperfusion models have observed reduced cardiomyocyte apoptosis and improved mitochondrial function following MOTS-c treatment. Researchers have also noted associations between MOTS-c levels and cardiovascular risk markers in human observational studies, though the mechanistic basis of these associations continues to be investigated.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBone \u0026amp; Musculoskeletal Research\u003c\/strong\u003e A growing body of literature has examined MOTS-c in the context of bone metabolism. Preclinical studies in ovariectomised rodent models — a standard model for postmenopausal bone loss — have observed that MOTS-c administration attenuates bone density reduction and modulates osteoblast-osteoclast balance. This has expanded MOTS-c research interest into osteoporosis biology and skeletal homeostasis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTyr-Gln-Ala-Val-Thr-Pro-Gly-Gly-Leu-Leu-Leu-Gly-Ala-Pro-Pro-Ile-Pro-Tyr-Arg-Ile-Pro-Ile-Pro-Gly-Ser-Ser-Val-Tyr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e1627580-64-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our MOTS-c is subject to a comprehensive, multi-stage quality control process prior to release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, sequence integrity, and molecular weight\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWe maintain complete batch traceability across synthesis, purification, and testing — providing the consistency researchers require for reproducible experimental results.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMOTS-c lyophilised powder should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS). Gently swirl the vial to dissolve — avoid vortexing, which can disrupt peptide structure. Once reconstituted, aliquot immediately into single-use volumes and store at –20°C. Repeated freeze-thaw cycles should be strictly avoided to preserve peptide integrity and biological activity in experimental settings.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should be conducted in compliance with standard laboratory safety protocols and applicable institutional or regulatory requirements.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eMOTS-c Within a Research Peptide Panel\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMOTS-c occupies a distinct and complementary position within a research peptide panel. While BPC-157 and TB-500 are primarily studied for their roles in tissue repair and wound healing, and GHK-Cu for its influence on gene expression and extracellular matrix remodelling, MOTS-c targets a fundamentally different biological axis — mitochondrial function, systemic metabolism, and cellular energy regulation. Together, these four peptides represent a broad and mechanistically diverse research toolkit, covering tissue repair, inflammation, genomic modulation, and metabolic biology.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. MOTS-c is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"10mg","offer_id":59643105640782,"sku":null,"price":28.99,"currency_code":"GBP","in_stock":true},{"title":"40mg","offer_id":59643105673550,"sku":null,"price":58.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_175906_cbc1a400-ce1f-486a-a179-a8b2ffa69983.png?v=1779451035"},{"product_id":"retatrutide","title":"Retatrutide","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eRetatrutide | LY3437943 | GIP\/GLP-1\/Glucagon Triple Receptor Agonist | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e LY3437943 \u003cstrong\u003eMechanism:\u003c\/strong\u003e Triple agonist — GIP, GLP-1, and glucagon receptor \u003cstrong\u003eMolecular Structure:\u003c\/strong\u003e 39-amino acid peptide with C20 fatty diacid moiety \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 2381272-73-5\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Retatrutide?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide (developmental code: LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company. It is a first-in-class triple hormone receptor agonist, designed as a single molecule that simultaneously activates three distinct receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). This multi-receptor mechanism distinguishes retatrutide from earlier generations of incretin-based research compounds — including GLP-1 mono-agonists such as semaglutide, and dual GIP\/GLP-1 agonists such as tirzepatide — by introducing glucagon receptor activation as an additional metabolic axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eStructurally, retatrutide is a 39-amino acid peptide conjugated to a C20 fatty diacid moiety, which confers an extended pharmacokinetic half-life suitable for once-weekly dosing in clinical research settings. Compared to endogenous GLP-1 and glucagon, retatrutide demonstrates lower potency at GLP-1 and glucagon receptors but substantially higher potency at the human GIP receptor — a pharmacological profile deliberately engineered to balance efficacy with tolerability.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide has progressed through Phase 2 clinical trials and into the Phase 3 TRIUMPH programme — one of the most significant and closely watched clinical development programmes in metabolic research. It currently represents the most clinically advanced triple hormone receptor agonist in the scientific literature and is among the most actively researched peptides in the field of metabolic and obesity science.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur retatrutide is supplied for research purposes only, synthesised under strict quality-controlled manufacturing conditions and verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). It is provided as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Clinical Trial Data\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide has one of the most substantive and rapidly evolving clinical research profiles of any peptide currently available for laboratory study. The compound has been evaluated in multiple randomised, placebo-controlled trials and has generated results that have been published in leading peer-reviewed journals including the New England Journal of Medicine, The Lancet, and Nature Medicine.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTriple Receptor Mechanism of Action\u003c\/strong\u003e Retatrutide's triple agonist mechanism operates across three complementary metabolic pathways. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and promotes insulin secretion in a glucose-dependent manner. GIP receptor activation enhances insulin secretion, modulates adipose tissue metabolism, and appears to synergise with GLP-1 activity to produce greater metabolic effects than either hormone alone — as demonstrated by the clinical performance of the dual agonist tirzepatide. The addition of glucagon receptor agonism introduces a third axis: increased energy expenditure, enhanced hepatic fat oxidation, and PCSK9-mediated reduction in LDL cholesterol. The net result of this triple activation is a broader and potentially more powerful metabolic response than earlier generation single or dual receptor agonists.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase 2 Obesity Trial — New England Journal of Medicine (2023)\u003c\/strong\u003e The pivotal Phase 2 obesity trial of retatrutide, published in the New England Journal of Medicine, enrolled 338 adults with obesity (BMI ≥30) or overweight with weight-related comorbidities. Participants received once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks. The results were notable even by the elevated standards of the modern incretin era. At 48 weeks, participants on the 8 mg dose achieved a mean body weight reduction of 22.8%, while those on the highest 12 mg dose achieved a mean reduction of 24.2% — compared to just 2.1% in the placebo group. Notably, 100% of participants in both the 8 mg and 12 mg groups achieved at least 5% body weight reduction, with 83% of the 12 mg group achieving reductions of 15% or more. These findings were accompanied by meaningful improvements in cardiometabolic markers including waist circumference, blood pressure, fasting glucose, HbA1c, insulin levels, and lipid profiles.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase 2 Type 2 Diabetes Trial — The Lancet (2023)\u003c\/strong\u003e A parallel Phase 2 trial published in The Lancet assessed retatrutide in 281 participants with type 2 diabetes over 36 weeks. At the highest dose of 12 mg, participants achieved mean body weight reduction of 16.9% compared to 3.0% with placebo. Glycaemic outcomes were equally striking: 77–82% of participants on retatrutide achieved euglycaemia (HbA1c ≤6.5%), and between 57–63% achieved body weight reductions of 15% or more. These results were described by lead investigators as the most significant weight loss outcomes reported in a clinical trial for type 2 diabetes at that time.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD\/NASH) — Nature Medicine (2024)\u003c\/strong\u003e A substudy of the Phase 2 obesity trial, published in Nature Medicine, examined retatrutide's effects in participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Results demonstrated substantial reductions in liver fat content at 24 weeks across all active doses, with the 8 mg and 12 mg doses producing mean relative liver fat reductions of 81.4% and 82.4% respectively, compared to a +0.3% change with placebo. At the highest doses, more than 90% of participants achieved normalisation of liver fat — findings of significant interest to researchers working in hepatology and fatty liver disease.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase 3 TRIUMPH Programme\u003c\/strong\u003e Retatrutide has now entered the Phase 3 TRIUMPH clinical programme, one of the most expansive trial programmes currently underway in obesity and metabolic medicine. The TRIUMPH programme is evaluating retatrutide across multiple indications including chronic weight management, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and MASLD. In December 2025, Eli Lilly announced positive topline results from TRIUMPH-4 — a 68-week Phase 3 trial in adults with obesity and knee osteoarthritis — in which retatrutide delivered average weight loss of up to 71.2 lbs alongside substantial reductions in osteoarthritis pain. Phase 3 trials across the broader TRIUMPH programme are projected to continue through 2025 and beyond, with regulatory submission timelines dependent on full data readouts.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiometabolic Research\u003c\/strong\u003e Beyond weight reduction, retatrutide's glucagon receptor component has attracted research interest for its cardiovascular effects. Phase 2 data demonstrated LDL cholesterol reductions of approximately 20%, a finding researchers have attributed to glucagon agonism-mediated effects on PCSK9 degradation. Reductions in systolic and diastolic blood pressure, triglycerides, and markers of insulin resistance have also been observed, positioning retatrutide as a subject of broad interest across cardiometabolic research.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eRetatrutide (LY3437943)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMechanism\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTriple agonist — GIP \/ GLP-1 \/ glucagon receptors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStructure\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e39-amino acid peptide, C20 fatty diacid conjugate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e2381272-73-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our retatrutide undergoes a rigorous multi-stage quality control process before release to researchers. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, fatty acid conjugation integrity, and sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing, giving researchers the confidence required for reproducible, high-quality experimental work.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide lyophilised powder should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS). Gently swirl the vial — do not vortex. Once reconstituted, aliquot immediately and store at –20°C. As with all peptide conjugates containing fatty acid moieties, repeated freeze-thaw cycles should be strictly avoided to preserve the structural integrity of the molecule and the reliability of experimental results.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eRetatrutide in Context: How It Compares to Other Research Peptides\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide occupies a distinct position within the broader research peptide landscape. Unlike tissue-focused peptides such as BPC-157 and TB-500, or genomic and matrix-remodelling peptides such as GHK-Cu, retatrutide operates as a hormonal receptor agonist targeting the systemic neuroendocrine regulation of metabolism. Its triple receptor mechanism sets it apart even from other incretin-class research compounds — representing the next evolutionary step beyond semaglutide (GLP-1 mono-agonist) and tirzepatide (GLP-1\/GIP dual agonist) in the hierarchy of metabolic peptide research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFor researchers building a comprehensive metabolic peptide panel, retatrutide complements MOTS-c — which operates at the mitochondrial and intracellular metabolic level — by providing a systemic hormonal signalling perspective on energy homeostasis and metabolic regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. Retatrutide is an investigational compound and is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"20mg","offer_id":59643105870158,"sku":null,"price":97.99,"currency_code":"GBP","in_stock":true},{"title":"40mg","offer_id":59643105935694,"sku":null,"price":188.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_174838_15734fbb-a993-46d2-bc3d-451a37913fd2.png?v=1779451042"},{"product_id":"hgh-peptide","title":"HGH Peptide","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHGH | Somatotropin | Recombinant Human Growth Hormone (rhGH) | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e Somatotropin, rhGH, Growth Hormone (GH), HGH \u003cstrong\u003eMolecular Structure:\u003c\/strong\u003e 191-amino acid single-chain polypeptide, four-helix bundle \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₉₉₀H₁₅₂₈N₂₆₂O₃₀₀S₇ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 22,124 Da \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C (refrigerated); –20°C for long-term storage \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 12629-01-5\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is HGH (Somatotropin)?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eHuman Growth Hormone (HGH), formally known as somatotropin, is a 191-amino acid single-chain polypeptide produced naturally by somatotropic cells within the anterior pituitary gland. It is one of the most structurally and functionally characterised hormones in human biology, and one of the longest-studied peptide hormones in the scientific literature — with research dating back to the 1950s. Its characteristic four-helix bundle structure is essential for binding to the growth hormone receptor (GHR), and this interaction underlies the full spectrum of its biological activity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eHGH production is tightly regulated by several complex feedback mechanisms in response to stress, exercise, nutrition, sleep, and growth hormone. The primary regulatory factors are growth hormone-releasing hormone (GHRH), produced in the hypothalamus; somatostatin, produced in various tissues throughout the body; and ghrelin, produced in the gastrointestinal tract. The net result of these interlocking regulatory signals is a pulsatile release pattern — with the largest secretory pulses occurring during deep sleep — that produces circulating HGH levels which peak during adolescence and decline progressively with age thereafter.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe recombinant human growth hormone (rhGH) supplied here is produced via recombinant DNA technology, yielding a molecule that is structurally identical to endogenous pituitary-derived somatotropin. This form — abbreviated rhGH in the scientific literature — has been the standard research-grade form since recombinant production methods superseded cadaveric extraction in the 1980s, and it remains the reference compound for the full body of modern growth hormone research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur HGH is manufactured under strict quality-controlled conditions, verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), and supplied as a lyophilised (freeze-dried) powder for optimal stability and shelf life.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eHGH has one of the most extensive and mature research profiles of any peptide in existence — with over six decades of published science spanning endocrinology, cell biology, metabolic medicine, musculoskeletal research, cardiovascular science, and neuroscience. Its central role in growth, metabolism, and tissue homeostasis makes it a foundational reference compound for researchers across a wide range of disciplines.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism of Action: Direct \u0026amp; Indirect Pathways\u003c\/strong\u003e HGH has two mechanisms of action: direct and indirect. The direct effects of HGH on the body occur through its binding to target cells, stimulating a response. The indirect effects occur primarily through insulin-like growth factor-1 (IGF-1), which hepatocytes secrete in response to elevated HGH binding to surface receptors. Once activated, the Janus-activated tyrosine kinases (JAKs) 1 and 2 bind to the latent cytoplasmic transcription factors STAT1, STAT3, and STAT5, and transport them into the nucleus, inducing increased gene transcription and metabolism to produce IGF-1 for release into the circulation. IGF-1 then mediates many of HGH's anabolic and growth-promoting effects at peripheral tissues. Researchers therefore study HGH and IGF-1 as an integrated axis rather than as independent compounds.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGrowth, Cell Proliferation \u0026amp; Tissue Development\u003c\/strong\u003e HGH stimulates growth, cell reproduction, and cell regeneration in humans and other animals, and also stimulates production of IGF-1 and increases the concentration of glucose and free fatty acids. In the context of preclinical research, this broad anabolic and mitogenic activity makes HGH a central reference compound in studies examining skeletal growth, organ development, chondrocyte and osteoblast biology, and the regulation of cell cycle progression. Its role in cartilage and long bone development via IGF-1-mediated growth plate stimulation remains one of the most studied areas of growth hormone biology.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic Research: Lipolysis, Glucose Homeostasis \u0026amp; Body Composition\u003c\/strong\u003e HGH exerts direct metabolic effects that are distinct from — and at times opposing to — its IGF-1-mediated growth effects. In preclinical and clinical research, HGH has been studied extensively for its lipolytic activity: it directly stimulates hormone-sensitive lipase in adipose tissue, promoting the mobilisation of free fatty acids as an energy substrate. Simultaneously, HGH exerts anti-insulin effects by reducing peripheral glucose uptake and increasing hepatic glucose output — effects that have made the GH–IGF-1 axis a central subject in diabetes research, insulin sensitivity modelling, and metabolic syndrome studies. Researchers use rhGH as a reference compound to investigate the interaction between growth factor signalling and insulin signalling pathways, as well as the downstream effects of GH excess and deficiency states on body composition, fat distribution, and lipid metabolism.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMusculoskeletal \u0026amp; Anabolic Research\u003c\/strong\u003e The role of HGH in skeletal muscle biology has been a subject of sustained research interest. Preclinical studies have investigated HGH's influence on satellite cell activation, myofibrillar protein synthesis, muscle hypertrophy, and recovery from muscle injury — effects largely mediated through the GH receptor and downstream IGF-1 signalling in muscle tissue. HGH is known to help improve and increase muscle mass through a process known as hypertrophy, and also boosts protein synthesis in the body. Research has also examined HGH's effects on nitrogen retention, amino acid transport, and the balance between protein synthesis and degradation in skeletal muscle — making it an important reference compound in studies examining sarcopenia, cachexia, and muscle wasting conditions.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eHGH's influence on bone mineral density and calcium metabolism has similarly attracted substantial research attention. It is also known to help improve calcium retention in cells, which leads to an increase in bone strength. Preclinical and translational research has investigated these effects in models of osteoporosis, fracture healing, and skeletal remodelling, with IGF-1 identified as a key mediator of HGH's osteoanabolic activity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eImmune System Research\u003c\/strong\u003e Another well-known function of HGH is the way it acts to stimulate the immune system. Preclinical research has investigated HGH's influence on thymic function, lymphocyte proliferation, natural killer cell activity, and cytokine production. The GH receptor is expressed on multiple immune cell types, and the GH–IGF-1 axis is now understood to play an important modulatory role in both innate and adaptive immunity. This has generated research interest in HGH's potential role in immune senescence — the age-associated decline in immune function — given the parallel decline in GH secretion observed with advancing age.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAgeing \u0026amp; GH Deficiency Research\u003c\/strong\u003e The progressive decline in HGH secretion with age — a phenomenon sometimes termed somatopause — is associated with a well-characterised constellation of metabolic and physiological changes including increased fat mass, reduced lean body mass, decreased bone density, impaired exercise capacity, and reduced quality of life. This relationship has made rhGH an important tool in ageing research, where it is used as a reference compound to investigate the biological consequences of GH deficiency and the mechanistic basis of age-related metabolic decline. Studies comparing GH-replete and GH-deficient animal models have been particularly valuable for delineating the specific contributions of the GH–IGF-1 axis to healthy ageing trajectories.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e The GH–IGF-1 axis exerts significant influence on cardiovascular structure and function, and has been studied extensively in both directions — deficiency and excess. In GH-deficient animal models, researchers have observed increased cardiovascular risk markers including dyslipidaemia, endothelial dysfunction, and reduced cardiac output. Conversely, GH excess models have been used to study the pathophysiology of acromegaly-related cardiomyopathy and hypertension. These two poles of the research landscape have contributed to a nuanced understanding of the dose-dependent and receptor-mediated cardiovascular effects of GH signalling.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eNeuroendocrinology \u0026amp; CNS Research\u003c\/strong\u003e GH receptors are expressed in multiple brain regions, and HGH has been investigated in preclinical models of cognitive function, neuroprotection, and neuroendocrine regulation. Research has examined the role of the GH–IGF-1 axis in hippocampal neurogenesis, synaptic plasticity, and the regulation of mood-associated neurotransmitter systems. These findings have contributed to a growing body of evidence suggesting that the age-related decline in GH secretion may have consequences for cognitive and neurological function beyond its well-characterised metabolic effects.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eHGH — Recombinant Human Growth Hormone (rhGH)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAlso Known As\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSomatotropin, Growth Hormone (GH)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStructure\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e191-amino acid single-chain polypeptide, four-helix bundle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₉₉₀H₁₅₂₈N₂₆₂O₃₀₀S₇\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e22,124 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or bacteriostatic water\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e2–8°C (short-term); –20°C (long-term, lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months lyophilised; use reconstituted solution within 28 days (2–8°C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e12629-01-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our recombinant HGH undergoes a rigorous multi-stage quality control and release process. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99% and correct isoform profile\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, molecular weight, and structural integrity of the 191-amino acid sequence\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSDS-PAGE\u003c\/strong\u003e — confirms correct molecular weight band and purity under denaturing conditions\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across fermentation, purification, and quality testing. Given the complexity of the rhGH molecule relative to shorter synthetic peptides, our multi-method QC approach is particularly important for confirming correct folding, isoform composition, and bioactivity-relevant structural integrity.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eLyophilised rhGH powder should be reconstituted by slowly adding sterile bacteriostatic water (0.3% benzyl alcohol) or sterile water for injection directly to the side of the vial — do not inject water directly onto the powder or vortex. Swirl gently until fully dissolved. The recommended reconstitution volume will depend on the experimental protocol and desired working concentration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOnce reconstituted, rhGH solution should be stored at 2–8°C and used within 28 days. For longer-term storage, aliquot the lyophilised powder prior to reconstitution and store at –20°C. Avoid repeated freeze-thaw cycles. As a larger, more complex protein than typical synthetic peptides, rhGH is more susceptible to degradation from heat, agitation, and improper storage — careful handling is essential to maintain research-grade integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHGH in the Context of the GH Research Axis\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eHGH is the central reference compound in a broader family of growth axis research tools. Researchers frequently study rhGH alongside related compounds to dissect the upstream and downstream components of GH signalling. Growth hormone-releasing hormone (GHRH) and its analogues — including sermorelin and CJC-1295 — represent the upstream secretagogue axis, while IGF-1 and its analogues (including IGF-1 LR3) represent the primary downstream effector pathway. Growth hormone-releasing peptides (GHRPs) such as GHRP-2 and GHRP-6 offer an alternative stimulatory approach via ghrelin receptor activation, while the HGH fragment 176–191 (AOD-9604) provides a tool for investigating the specific lipolytic domain of the molecule in isolation from its growth-promoting effects.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin our broader catalogue, rhGH occupies a distinct endocrine research niche relative to the tissue-repair focused peptides BPC-157 and TB-500, the genomic and matrix remodelling compound GHK-Cu, the mitochondrial metabolic peptide MOTS-c, the systemic hormonal triple agonist retatrutide, and the intracellular NNMT inhibitor 5-Amino-1MQ. Together, these compounds offer researchers a diverse, mechanistically broad toolkit spanning endocrine signalling, tissue biology, metabolic regulation, and cellular ageing research.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. Recombinant human growth hormone is a prescription-only medicine in most jurisdictions and is not approved for non-prescription or non-therapeutic human use by the FDA, EMA, or any other regulatory authority. It is not a supplement or food product. This product must not be administered to humans or animals outside of appropriately approved and supervised clinical or veterinary contexts. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"10iu","offer_id":59726767849806,"sku":null,"price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260224_165928_843290e3-a35a-4a46-8a61-4d3b8b91ba27.jpg?v=1780245162"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/collections\/hf_20260513_092235_0d4a96eb-a275-4e18-ab26-3f41a064ae06.png?v=1780245157","url":"https:\/\/nexyralab.com\/collections\/metabolic-fat-loss-research.oembed","provider":"Nexyralab.com","version":"1.0","type":"link"}